Two recently identified and tested gene-expression signatures may guide clinicians in selecting which patients may show a response to palbocicib, according to findings presented at the IMPAKT Breast Cancer Conference held 7–9 May 2015 in Brussels, Belgium.
Click here to read the article in full.
Source: ESMO
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.